DE2815926A1 - Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel - Google Patents
Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittelInfo
- Publication number
- DE2815926A1 DE2815926A1 DE19782815926 DE2815926A DE2815926A1 DE 2815926 A1 DE2815926 A1 DE 2815926A1 DE 19782815926 DE19782815926 DE 19782815926 DE 2815926 A DE2815926 A DE 2815926A DE 2815926 A1 DE2815926 A1 DE 2815926A1
- Authority
- DE
- Germany
- Prior art keywords
- group
- oxy
- hydrogen
- carbazolyl
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims description 34
- 238000000034 method Methods 0.000 title claims description 13
- 238000004519 manufacturing process Methods 0.000 title description 4
- 229940126601 medicinal product Drugs 0.000 title 1
- -1 bicyclic aryl radical Chemical class 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000003435 aroyl group Chemical group 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 3
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 3
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 125000002950 monocyclic group Chemical group 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 2
- 230000000304 vasodilatating effect Effects 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- SVWKIGRDISDRLO-UHFFFAOYSA-N 4-(oxiran-2-ylmethoxy)-9h-carbazole Chemical compound C=1C=CC=2NC3=CC=CC=C3C=2C=1OCC1CO1 SVWKIGRDISDRLO-UHFFFAOYSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 14
- 239000013078 crystal Substances 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000002844 melting Methods 0.000 description 11
- 230000008018 melting Effects 0.000 description 11
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 238000007327 hydrogenolysis reaction Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 150000004780 naphthols Chemical class 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- QWBBPBRQALCEIZ-UHFFFAOYSA-N 2,3-dimethylphenol Chemical compound CC1=CC=CC(O)=C1C QWBBPBRQALCEIZ-UHFFFAOYSA-N 0.000 description 2
- IKIYPTDCNNXUJN-UHFFFAOYSA-N 2-(2-methylsulfanylphenoxy)ethanamine Chemical compound CSC1=CC=CC=C1OCCN IKIYPTDCNNXUJN-UHFFFAOYSA-N 0.000 description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 150000001728 carbonyl compounds Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 229920006158 high molecular weight polymer Polymers 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005245 sintering Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GBBBWTDKOLEAOC-UHFFFAOYSA-N 1-(2-methoxyphenoxy)propan-2-one Chemical compound COC1=CC=CC=C1OCC(C)=O GBBBWTDKOLEAOC-UHFFFAOYSA-N 0.000 description 1
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- KMXCVCHKPIAYOI-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride;pyridine Chemical compound C1=CC=NC=C1.CC(C)(C)C(Cl)=O KMXCVCHKPIAYOI-UHFFFAOYSA-N 0.000 description 1
- JHNURUNMNRSGRO-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-3-ylmethanamine Chemical compound C1=CC=C2OC(CN)COC2=C1 JHNURUNMNRSGRO-UHFFFAOYSA-N 0.000 description 1
- QFFKNTCASXEPOQ-UHFFFAOYSA-N 2-(2,3-dimethylphenoxy)ethanamine Chemical compound CC1=CC=CC(OCCN)=C1C QFFKNTCASXEPOQ-UHFFFAOYSA-N 0.000 description 1
- QDAOLZRIBDCHRR-UHFFFAOYSA-N 2-(2,6-dimethoxyphenoxy)acetonitrile Chemical compound COC1=CC=CC(OC)=C1OCC#N QDAOLZRIBDCHRR-UHFFFAOYSA-N 0.000 description 1
- BDOKKFIYLQAJOF-UHFFFAOYSA-N 2-(2,6-dimethoxyphenoxy)ethanamine Chemical compound COC1=CC=CC(OC)=C1OCCN BDOKKFIYLQAJOF-UHFFFAOYSA-N 0.000 description 1
- NAPNYPMMDVRKGM-UHFFFAOYSA-N 2-(2-chlorophenoxy)ethanamine Chemical compound NCCOC1=CC=CC=C1Cl NAPNYPMMDVRKGM-UHFFFAOYSA-N 0.000 description 1
- OOKCBENPEIHOJG-UHFFFAOYSA-N 2-(2-ethoxyphenoxy)ethanamine Chemical compound CCOC1=CC=CC=C1OCCN OOKCBENPEIHOJG-UHFFFAOYSA-N 0.000 description 1
- CKJRKLKVCHMWLV-UHFFFAOYSA-N 2-(2-methoxyphenoxy)ethanamine Chemical compound COC1=CC=CC=C1OCCN CKJRKLKVCHMWLV-UHFFFAOYSA-N 0.000 description 1
- BIWHLVXMIXGLJA-UHFFFAOYSA-N 2-(2-methoxyphenoxy)propan-1-amine Chemical compound COC1=CC=CC=C1OC(C)CN BIWHLVXMIXGLJA-UHFFFAOYSA-N 0.000 description 1
- WSWPCNMLEVZGSM-UHFFFAOYSA-N 2-(2-methoxyphenyl)ethanamine Chemical compound COC1=CC=CC=C1CCN WSWPCNMLEVZGSM-UHFFFAOYSA-N 0.000 description 1
- FWTYMSQXRXREFR-UHFFFAOYSA-N 2-(2-methoxyphenyl)sulfanylethanamine Chemical compound COC1=CC=CC=C1SCCN FWTYMSQXRXREFR-UHFFFAOYSA-N 0.000 description 1
- DXYUDCFZHJXQQR-UHFFFAOYSA-N 2-(2-methylphenoxy)ethanamine Chemical compound CC1=CC=CC=C1OCCN DXYUDCFZHJXQQR-UHFFFAOYSA-N 0.000 description 1
- GCBARCBKJKKWDS-UHFFFAOYSA-N 2-(2-methylsulfanylphenoxy)acetonitrile Chemical compound CSC1=CC=CC=C1OCC#N GCBARCBKJKKWDS-UHFFFAOYSA-N 0.000 description 1
- MWOLPDQWBBJNJU-UHFFFAOYSA-N 2-(3-methoxyphenoxy)ethanamine Chemical compound COC1=CC=CC(OCCN)=C1 MWOLPDQWBBJNJU-UHFFFAOYSA-N 0.000 description 1
- IGGVZLIHUYNMNQ-UHFFFAOYSA-N 2-(3-methylphenoxy)ethanamine Chemical compound CC1=CC=CC(OCCN)=C1 IGGVZLIHUYNMNQ-UHFFFAOYSA-N 0.000 description 1
- YXRCDWIZAGWUBL-UHFFFAOYSA-N 2-(4-methoxyphenoxy)ethanamine Chemical compound COC1=CC=C(OCCN)C=C1 YXRCDWIZAGWUBL-UHFFFAOYSA-N 0.000 description 1
- PMADTOCMHRNTRG-UHFFFAOYSA-N 2-(4-tert-butylphenoxy)ethanamine Chemical compound CC(C)(C)C1=CC=C(OCCN)C=C1 PMADTOCMHRNTRG-UHFFFAOYSA-N 0.000 description 1
- LJFLKLZPTIKGGE-UHFFFAOYSA-N 2-(5-fluoro-2-methoxyphenoxy)ethanol Chemical compound COC1=CC=C(F)C=C1OCCO LJFLKLZPTIKGGE-UHFFFAOYSA-N 0.000 description 1
- SOOARYARZPXNAL-UHFFFAOYSA-N 2-(Methylthio)phenol Chemical compound CSC1=CC=CC=C1O SOOARYARZPXNAL-UHFFFAOYSA-N 0.000 description 1
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 1
- IMLAIXAZMVDRGA-UHFFFAOYSA-N 2-phenoxyethanamine Chemical compound NCCOC1=CC=CC=C1 IMLAIXAZMVDRGA-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- XPQIPUZPSLAZDV-UHFFFAOYSA-N 2-pyridylethylamine Chemical compound NCCC1=CC=CC=N1 XPQIPUZPSLAZDV-UHFFFAOYSA-N 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- YEGXZBYGDXGWJU-UHFFFAOYSA-N 3-(2-methoxyphenyl)propanoyl chloride Chemical compound COC1=CC=CC=C1CCC(Cl)=O YEGXZBYGDXGWJU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MHIAMONBYDFGFO-UHFFFAOYSA-N 4-(2-aminoethoxy)benzamide Chemical compound NCCOC1=CC=C(C(N)=O)C=C1 MHIAMONBYDFGFO-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- PPJKLEQAFZWIQY-UHFFFAOYSA-N 5-fluoro-2-methoxyphenol Chemical compound COC1=CC=C(F)C=C1O PPJKLEQAFZWIQY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 101150117856 amiB gene Proteins 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 238000006480 benzoylation reaction Methods 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 150000001716 carbazoles Chemical class 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- VGGRCVDNFAQIKO-UHFFFAOYSA-N formic anhydride Chemical compound O=COC=O VGGRCVDNFAQIKO-UHFFFAOYSA-N 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- FZJCXIDLUFPGPP-UHFFFAOYSA-N propan-2-ol;toluene Chemical compound CC(C)O.CC1=CC=CC=C1 FZJCXIDLUFPGPP-UHFFFAOYSA-N 0.000 description 1
- UMSVPCYSAUKCAZ-UHFFFAOYSA-N propane;hydrochloride Chemical compound Cl.CCC UMSVPCYSAUKCAZ-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000005554 pyridyloxy group Chemical group 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 125000005624 silicic acid group Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (28)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19782815926 DE2815926A1 (de) | 1978-04-13 | 1978-04-13 | Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| CA324,667A CA1129416A (en) | 1978-04-13 | 1979-04-02 | Carbazolyl-(4)-oxypropanolamine derivatives |
| ES479396A ES479396A1 (es) | 1978-04-13 | 1979-04-06 | Procedimiento para la preparacion de derivados de carbazolil-(4)-oxi-propanolamina. |
| DK141979A DK154555C (da) | 1978-04-13 | 1979-04-06 | Analogifremgangsmaade til fremstilling af carbazolyl-(4)-oxy-propanolaminderivater eller deres farmakologisk anvendelige salte |
| SU792745301A SU810079A3 (ru) | 1978-04-13 | 1979-04-06 | Способ получени производныхКАРбАзОлил (4)-ОКСи-пРОпАНОлАМиНАили иХ СОлЕй (ЕгО ВАРиАНТы) |
| AU45820/79A AU522975B2 (en) | 1978-04-13 | 1979-04-06 | Carbazolyl-(4)-oxypropanolamine derivatives |
| FI791142A FI70406C (fi) | 1978-04-13 | 1979-04-06 | Foerfarande foer framstaellning av farmaceutiskt aktivt karbazolyl-(4)-oxipropanolamin-derivat |
| DE7979101063T DE2960553D1 (en) | 1978-04-13 | 1979-04-07 | Derivatives of carbazolyl-4-oxypropanolamine, methods for their preparation and medicines containing them |
| EP79101063A EP0004920B1 (de) | 1978-04-13 | 1979-04-07 | Carbazolyl-(4)-oxy-propanolamin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| IL57020A IL57020A (en) | 1978-04-13 | 1979-04-08 | Carbazolyl-(4)-oxypropanolamine derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
| DD79212096A DD143607A5 (de) | 1978-04-13 | 1979-04-09 | Verfahren zur herstellung neuer carbazolyl-(4)-oxy-propanolamin-derivate |
| CS792434A CS227007B2 (en) | 1978-04-13 | 1979-04-10 | Method of preparing carbazol-4-yl oxypropanolamine derivatives |
| ZA791732A ZA791732B (en) | 1978-04-13 | 1979-04-11 | Carbazolyl-(4)-oxypropanolamine derivatives,preparation thereof and pharmaceutical compositions containing these compounds |
| JP4311979A JPS54157558A (en) | 1978-04-13 | 1979-04-11 | Novel carbazolyll*4**oxyypropanolamine derivative*its manufacture and drug containing it and having vasodilatation and*or betaaacceptor occlusion activity |
| AT0276279A AT375639B (de) | 1978-04-13 | 1979-04-12 | Verfahren zur herstellung von neuen carbazolyl-(4)-oxy-propanolamin-derivaten und ihren salzen |
| HU79BO1774A HU179433B (en) | 1978-04-13 | 1979-04-12 | Process for preparing new carbazolyl-/4/-oxy-propanolamine derivatives and pharmaceutical compositions containing thereof |
| CS792434A CS227047B2 (cs) | 1978-04-13 | 1982-08-20 | Způsob výroby derivátů karbazol-4-yloxypropanolaminu |
| US06/479,921 US4503067A (en) | 1978-04-13 | 1983-04-04 | Carbazolyl-(4)-oxypropanolamine compounds and therapeutic compositions |
| SG52284A SG52284G (en) | 1978-04-13 | 1984-07-20 | Derivatives of carbazolyl-4-oxypropanolamine,methods for their preparation and medicines containing them |
| HK23/85A HK2385A (en) | 1978-04-13 | 1985-01-10 | Derivatives of carbazolyl-4-oxypropanolamine, methods for their preparation and medicines containing them |
| JP62076548A JPS63258416A (ja) | 1978-04-13 | 1987-03-31 | カルバゾリル−（４）−オキシ−プロパノ−ルアミン誘導体を含有し血管拡張作用及び／又はβ−受容体閉塞作用を有する薬剤 |
| CS914200A CS420091A3 (en) | 1978-04-13 | 1991-12-31 | Derivatives of carbazol-4-yloxy-propanol amine, process of their preparation and medicament containing these compounds |
| MX9203380A MX9203380A (es) | 1978-04-13 | 1992-06-25 | Derivados de carbazolil-(4)-oxi-propanolamina y composiciones farmaceuticas que los contienen. |
| LV930454A LV5234A3 (lv) | 1971-10-29 | 1993-06-01 | (Karbazolil-4-oksi)propanolamina atvasinajumu un to saju iegusanas panemiens (varianti) |
| LU88320C LU88320I2 (de) | 1978-04-13 | 1993-06-22 | Carvedilol (Dilatred /Dimitone) |
| NL930110C NL930110I2 (nl) | 1978-04-13 | 1993-06-29 | Carbazolyl-(4)-oxypropanolamine-derivaten, werkwijze ter bereiding daarvan en geneesmiddelen, die deze verbindingen bevatten. |
| LTRP1124A LT2628B (lt) | 1978-04-13 | 1993-09-27 | Karbazolil-(4)-oksi-propanolamino dariniu arba ju drusku gavimo budas (jo variantai) |
| BG098612A BG61419B2 (bg) | 1978-04-13 | 1994-02-28 | Производни на карбазолил-(4)-окси-пропаноламина,метод за получаването им и лекарствено средство,съдържащо тези съединения |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19782815926 DE2815926A1 (de) | 1978-04-13 | 1978-04-13 | Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2815926A1 true DE2815926A1 (de) | 1979-10-18 |
Family
ID=6036838
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19782815926 Withdrawn DE2815926A1 (de) | 1971-10-29 | 1978-04-13 | Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE7979101063T Expired DE2960553D1 (en) | 1978-04-13 | 1979-04-07 | Derivatives of carbazolyl-4-oxypropanolamine, methods for their preparation and medicines containing them |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE7979101063T Expired DE2960553D1 (en) | 1978-04-13 | 1979-04-07 | Derivatives of carbazolyl-4-oxypropanolamine, methods for their preparation and medicines containing them |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4503067A (en:Method) |
| EP (1) | EP0004920B1 (en:Method) |
| JP (2) | JPS54157558A (en:Method) |
| AT (1) | AT375639B (en:Method) |
| AU (1) | AU522975B2 (en:Method) |
| BG (1) | BG61419B2 (en:Method) |
| CA (1) | CA1129416A (en:Method) |
| CS (2) | CS227007B2 (en:Method) |
| DD (1) | DD143607A5 (en:Method) |
| DE (2) | DE2815926A1 (en:Method) |
| DK (1) | DK154555C (en:Method) |
| ES (1) | ES479396A1 (en:Method) |
| FI (1) | FI70406C (en:Method) |
| HK (1) | HK2385A (en:Method) |
| HU (1) | HU179433B (en:Method) |
| IL (1) | IL57020A (en:Method) |
| LT (1) | LT2628B (en:Method) |
| LU (1) | LU88320I2 (en:Method) |
| MX (1) | MX9203380A (en:Method) |
| NL (1) | NL930110I2 (en:Method) |
| SG (1) | SG52284G (en:Method) |
| SU (1) | SU810079A3 (en:Method) |
| ZA (1) | ZA791732B (en:Method) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4985454A (en) * | 1983-05-26 | 1991-01-15 | Boehringer Mannheim Gmbh | Process for the preparation of optically-active carbazole derivatives, new R- and S-carbazole derivatives and pharmaceutical compositions containing these compounds |
| EP0893440A1 (en) * | 1997-07-22 | 1999-01-27 | Roche Diagnostics GmbH | Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it |
| EP0918055A1 (en) * | 1997-11-24 | 1999-05-26 | Egis Gyogyszergyar Rt. | Process and intermediates for preparing 1-[9'H-carbazol-4'-yloxy]-3-[ 2''-(2'''- methoxy -phenoxy)-ethyl)-amino]-propan-2-ol[carvedilol] |
| US6730326B2 (en) | 1997-07-22 | 2004-05-04 | Roche Diagnostics Gmbh | Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it |
| WO2004041783A1 (en) * | 2002-11-08 | 2004-05-21 | Zentiva, A.S. | Process for preparation of carvedilol |
| RU2245875C2 (ru) * | 1997-11-24 | 2005-02-10 | Эгиш Дьёдьсердьяр Рт. | Способ получения фармацевтического продукта |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3131146A1 (de) * | 1981-08-06 | 1983-02-24 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue heteroaryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE3300933A1 (de) * | 1983-01-13 | 1984-07-19 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verwendung von d,l- und d-carazolol als antiglaukommittel sowie arzneimittel, die diese stoffe enthalten |
| GB9113802D0 (en) * | 1991-06-26 | 1991-08-14 | Smithkline Beecham Plc | Medicaments |
| US20030036980A1 (en) * | 2001-08-14 | 2003-02-20 | Wren Stephen C. | System for marketing goods and services utilizing computerized central and remote facilities |
| ZA938897B (en) * | 1992-12-01 | 1994-08-01 | Smithkline Beecham Corp | Antioxidant neuroprotective use of and method of treatment using hydroxycarbazole compounds |
| US5405863A (en) * | 1992-12-01 | 1995-04-11 | Smithkline Beecham Corporation | Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds |
| WO1994020096A1 (en) * | 1993-03-05 | 1994-09-15 | Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beckman Corporation Limited | Method of employing carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation |
| US5308862A (en) * | 1993-03-05 | 1994-05-03 | Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 | Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation |
| US5393772A (en) * | 1993-11-24 | 1995-02-28 | Boehringer Mannheim Pharmaceuticals Corporation | Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation |
| US5760069A (en) | 1995-02-08 | 1998-06-02 | Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 | Method of treatment for decreasing mortality resulting from congestive heart failure |
| ZA967892B (en) * | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| US6177430B1 (en) | 1997-03-27 | 2001-01-23 | Pfizer Inc | Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia |
| DE19628335A1 (de) * | 1996-07-13 | 1998-01-15 | Boehringer Mannheim Gmbh | Verwendung von Carbazolyl-(4)-oxy-propanolamin-Derivaten zur topischen Behandlung von peripheren Durchblutungsstörungen |
| BR9711228A (pt) * | 1996-08-23 | 2000-01-11 | Boeringer Mannheim Pharmaceuti | Método para a inibição da expressão de fas |
| ES2171839T3 (es) | 1996-09-05 | 2002-09-16 | Lilly Co Eli | Analogos de carbazol como agonistas adrenergicos selectivos de beta3. |
| US5808080A (en) * | 1996-09-05 | 1998-09-15 | Eli Lilly And Company | Selective β3 adrenergic agonists |
| AU4751897A (en) | 1996-10-09 | 1998-05-05 | Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership No. 1 | Method for inhibiting stress-activated protein kinases |
| ZA989365B (en) * | 1997-10-15 | 1999-04-15 | Boehringer Mannheim Pharm Corp | Preparation for treating alzheimer's disease |
| JP2001522794A (ja) * | 1997-11-12 | 2001-11-20 | ベーリンガー・マンハイム・ファーマシューティカルズ・コーポレイション−スミスクライン・ベックマン・コーポレイション・リミテッド・パートナーシップ・ナンバー１ | カルベジロールの新規経口剤形 |
| CO5011072A1 (es) | 1997-12-05 | 2001-02-28 | Lilly Co Eli | Etanolaminas pirazinil substituidas como agfonistas de los receptores |
| EP1069896B1 (en) * | 1998-04-09 | 2003-08-06 | Roche Diagnostics GmbH | Carvedilol-galenics |
| EP0968714A1 (de) * | 1998-07-02 | 2000-01-05 | Roche Diagnostics GmbH | Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen |
| US6664284B2 (en) | 1998-07-23 | 2003-12-16 | Roche Diagnostics Gmbh | Stabilized carvedilol injection solution |
| DE19833119A1 (de) * | 1998-07-23 | 2000-01-27 | Roche Diagnostics Gmbh | Spritzfertige Injektionslösungen enthaltend Carvedilol |
| US6291506B1 (en) | 1998-08-04 | 2001-09-18 | Wisconsin Alumni Research Foundation | Method of reducing retinal ganglion cell degeneration |
| PE20001302A1 (es) | 1998-11-27 | 2000-11-30 | Hoffmann La Roche | Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida |
| MY125942A (en) | 1999-09-07 | 2006-09-29 | Upjohn Co | Aminoalkoxy carbazoles for the treatment of cns diseases |
| US6515010B1 (en) | 1999-11-15 | 2003-02-04 | Smithkline Beecham Corporation | Carvedilol methanesulfonate |
| WO2001074356A1 (en) * | 2000-04-03 | 2001-10-11 | F. Hoffmann-La Roche Ag | Concentrated solutions of carvedilol |
| US20010036959A1 (en) * | 2000-04-03 | 2001-11-01 | Gabel Rolf Dieter | Carvedilol-hydrophilic solutions |
| DK174645B1 (da) * | 2000-05-18 | 2003-08-04 | Gea Farmaceutisk Fabrik As | Fremgangsmåde og mellemprodukter til fremstillingen af 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol, carvedilol og syreadditionssalte deraf |
| KR20080015888A (ko) | 2000-06-28 | 2008-02-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 카르베딜올 |
| EP1655285A1 (en) * | 2000-06-28 | 2006-05-10 | Teva Pharmaceutical Industries Ltd. | Method for preparation of a crystalline form of carvedilol (form II) |
| GB0106953D0 (en) * | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| US20050009897A1 (en) * | 2001-04-02 | 2005-01-13 | Karen Anderson | Method of treatment |
| IN191028B (en:Method) * | 2001-05-17 | 2003-09-13 | Sun Pharmaceutical Ind Ltd | |
| EP1406614B1 (en) * | 2001-07-13 | 2006-06-07 | Smithkline Beecham Corporation | Carvedilol polymorph |
| US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
| EP2957281A1 (en) * | 2001-09-21 | 2015-12-23 | Egalet Ltd. | Polymer release system |
| CA2460486A1 (en) * | 2001-09-28 | 2003-04-10 | F. Hoffmann-La Roche Ag | Pseudopolymorphic forms of carvedilol |
| WO2003028718A1 (en) * | 2001-10-01 | 2003-04-10 | Smithkline Beecham Corporation | Novel formulations of carvedilol |
| US8101209B2 (en) * | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| AU2003205146A1 (en) * | 2002-01-15 | 2003-07-30 | Teva Pharmaceutical Industries Ltd. | Crystalline solids of carvedilol and processes for their preparation |
| JP4625637B2 (ja) | 2002-02-22 | 2011-02-02 | シャイア エルエルシー | 活性物質送達系及び活性物質を保護し投与する方法 |
| WO2003092622A2 (en) * | 2002-04-30 | 2003-11-13 | Sb Pharmco Puerto Rico Inc. | Carvedilol monocitrate monohydrate |
| AU2003231307A1 (en) * | 2002-05-03 | 2003-11-17 | Smithkline Beecham Pharmco Puerto Rico, Inc. | Carvedilol pharmasolve solvate |
| AU2003231306A1 (en) * | 2002-05-03 | 2003-11-17 | Smithkline Beecham Pharmco Puerto Rico, Inc. | Carvedilol formulations |
| CA2492084A1 (en) | 2002-06-27 | 2004-01-08 | Sb Pharmco Puerto Rico Inc. | Carvedilol hydobromide |
| MXPA04012923A (es) * | 2002-06-27 | 2005-03-31 | Sb Pharmco Inc | Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento. |
| US20040152756A1 (en) * | 2002-07-15 | 2004-08-05 | Wei Chen | Carvedilol polymorph |
| US20060013877A1 (en) * | 2002-07-22 | 2006-01-19 | Nanohybrid Co., Ltd. | Hybrid of itraconazole, cyclosporine or carvedilol with a layered silicate and a process for preparing the same |
| DE60336485D1 (de) | 2002-08-19 | 2011-05-05 | Pfizer | Kombinationstherapie gegen hyperproliferative erkrankungen |
| US6632832B1 (en) | 2002-09-10 | 2003-10-14 | Dabur Research Foundation | Anti-cancer activity of carvedilol and its isomers |
| EP1562552A1 (en) * | 2002-11-08 | 2005-08-17 | Egalet A/S | Controlled release carvedilol compositions |
| WO2004094378A1 (en) * | 2003-04-21 | 2004-11-04 | Matrix Laboratories Ltd | Process for the preparation of carvedilol form-ii |
| US7923467B2 (en) * | 2003-05-30 | 2011-04-12 | Ranbaxy Laboratories, Inc. | Substituted pyrrole derivatives and their use as HMG-CO inhibitors |
| US7482471B2 (en) * | 2003-06-20 | 2009-01-27 | Sun Pharmaceutical Industries Limited | Process for preparation of 1-[9H-carbazol-4-yloxy]-3-[{2-(2-(-methoxy)phenoxy)-ethyl}-amino]-propan-2-ol |
| US20050037063A1 (en) * | 2003-07-21 | 2005-02-17 | Bolton Anthony E. | Combined therapies |
| US20050169994A1 (en) * | 2003-11-25 | 2005-08-04 | Burke Matthew D. | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
| WO2005051383A1 (en) * | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Carvedilol salts, corresponding compositions, methods of delivery and/or treatment |
| CA2547137A1 (en) * | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
| US20070191456A1 (en) * | 2004-04-22 | 2007-08-16 | Tarur Venkatasubramanian R | Novel process for the preparation of 1-(9h-carbazol-4-yloxy)-3-[[2-(-methoxyphenoxy)-ethyl] amino]-propan-2-ol |
| GB0411273D0 (en) * | 2004-05-20 | 2004-06-23 | Cipla Ltd | Process and product |
| JP2008521805A (ja) * | 2004-11-30 | 2008-06-26 | アーテシアン セラピューティクス， インコーポレイテッド | β−アドレナリン作用性受容体およびホスホジエステラーゼに対する阻害活性を有する強心性化合物 |
| JP2008523025A (ja) * | 2004-12-09 | 2008-07-03 | ザック システム エス．ピー．エー． | カルベジロール及びそのエナンチオマーの調製プロセス |
| US20070027202A1 (en) * | 2005-06-07 | 2007-02-01 | Ashok Kumar | Process for the preparation of carvedilol and its salts |
| EP1781611A1 (en) * | 2005-06-09 | 2007-05-09 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of carvedilol and processes for their preparation |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| ZA200803226B (en) | 2005-10-13 | 2009-11-25 | Orchid Res Lab Ltd | Heterocyclic Compounds as Pstat3/IL-6 Inhibitors |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US8026377B2 (en) * | 2005-11-08 | 2011-09-27 | Ranbaxy Laboratories, Limited | Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
| WO2008020314A2 (en) * | 2006-03-14 | 2008-02-21 | Ranbaxy Laboratories Limited | Statin stabilizing dosage formulations |
| US8703804B2 (en) | 2006-03-26 | 2014-04-22 | Uti Limited Partnership | Ryanodine receptor inhibitors and methods relating thereto |
| WO2008002683A2 (en) * | 2006-06-28 | 2008-01-03 | Teva Pharmaceutical Industries Ltd. | Polymorphous forms of carvedilol phosphate |
| WO2008010087A2 (en) * | 2006-07-14 | 2008-01-24 | Ranbaxy Laboratories Limited | Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof |
| WO2008038301A1 (en) * | 2006-09-26 | 2008-04-03 | Morepen Laboratories Limited | A process for the preparation of carvedilol |
| US20080292695A1 (en) * | 2006-12-01 | 2008-11-27 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
| WO2008070496A2 (en) | 2006-12-01 | 2008-06-12 | Bristol-Myers Squibb Company | N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| US20090028935A1 (en) * | 2006-12-01 | 2009-01-29 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
| WO2008084494A1 (en) * | 2007-01-08 | 2008-07-17 | Matrix Laboratories Limited | Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same |
| US20100291205A1 (en) * | 2007-01-16 | 2010-11-18 | Egalet A/S | Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse |
| CZ302357B6 (cs) * | 2007-01-26 | 2011-03-30 | Zentiva, A. S. | Zpusob cištení Carvedilolu |
| WO2008105794A1 (en) * | 2007-02-26 | 2008-09-04 | Teva Pharmaceutical Industries Ltd. | Process for the purification of carvedilol or its salts thereof |
| US20080249317A1 (en) * | 2007-04-04 | 2008-10-09 | Apotex Inc. | Novel amorphous form of carvedilol phosphate and processes for the preparation thereof |
| WO2008142703A1 (en) * | 2007-05-17 | 2008-11-27 | Wanbury Limited | A novel cost effective process for production of carvedilol phosphate |
| EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| US8278461B2 (en) * | 2007-08-21 | 2012-10-02 | Lupin Limited | Stable amorphous form of carvedilol dihydrogen phosphate with stabilizer |
| WO2009035535A2 (en) * | 2007-09-07 | 2009-03-19 | Scinopharm Taiwan Ltd. | Method of crystallizing carvedilol phosphate and the product thereof |
| US20090076116A1 (en) * | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched carvediolo |
| US20090111998A1 (en) * | 2007-10-25 | 2009-04-30 | Srinivas Reddy Gade | Process for the preparation of carvedilol dihydrogen phosphate hemihydrate and pharmaceutical compositions thereof |
| WO2009110004A1 (en) | 2008-03-04 | 2009-09-11 | Lupin Limited | Stable pharmaceutical compositions qf carvedilol |
| WO2009115902A1 (en) * | 2008-03-19 | 2009-09-24 | Cadila Pharmaceuticals Ltd. | Process for the preparation of carvedilol via silyl protection of substituted amine |
| WO2009115906A2 (en) * | 2008-03-19 | 2009-09-24 | Cadila Pharmaceuticals Ltd. | An improved process for preparation of carvedilol involving halohydrin derivative |
| WO2009122425A1 (en) * | 2008-04-04 | 2009-10-08 | Shodhana Laboratories Limited | Novel crystalline form of carvedilol dihydrogen phosphate and related processes |
| US7763645B2 (en) * | 2008-05-23 | 2010-07-27 | Wanbury Limited | Carvedilol dihydrogen phosphate monohydrate |
| WO2010092589A2 (en) * | 2008-05-26 | 2010-08-19 | Alkem Laboratories Ltd. | Process for preparation of amorphous carvedilol phosphate |
| CA2751667C (en) | 2009-02-06 | 2016-12-13 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| CA2766179A1 (en) | 2009-06-24 | 2010-12-29 | Egalet Ltd. | Controlled release formulations |
| TWI415604B (zh) | 2009-09-29 | 2013-11-21 | Tsh Biopharm Corp Ltd | 調控釋放卡菲蒂羅劑型 |
| US20110229564A1 (en) * | 2010-03-22 | 2011-09-22 | Amneal Pharmaceuticals, L.L.C. | Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof |
| JP6063477B2 (ja) | 2011-12-16 | 2017-01-18 | スリーエム イノベイティブ プロパティズ カンパニー | オキシラン含有ビスアンヒドロヘキシトール誘導体及びその使用 |
| EP2877161A1 (en) | 2012-07-06 | 2015-06-03 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
| US8492426B1 (en) * | 2012-07-12 | 2013-07-23 | Anis Ahmad | Use of carvedilol for treatment of diabetes mellitus |
| AU2014255381A1 (en) | 2013-04-17 | 2015-10-08 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| US10357476B1 (en) | 2018-10-30 | 2019-07-23 | Anis Ahmad | Method for treating coronary artery disease |
| CN113574055B (zh) | 2019-01-18 | 2024-07-23 | 阿斯利康(瑞典)有限公司 | Pcsk9抑制剂及其使用方法 |
| CN111170997A (zh) * | 2019-12-31 | 2020-05-19 | 广州医科大学 | 咔唑类化合物及其制备方法和应用 |
| CN113372260A (zh) * | 2021-07-05 | 2021-09-10 | 大连蒙迪科技有限公司 | 一种卡维地洛杂质的合成方法 |
| CN115960032A (zh) * | 2021-10-08 | 2023-04-14 | 复旦大学 | 具有β-arrestin偏向性激动活性的芳氧丙醇胺类β-肾上腺素受体配基及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1834015A (en) * | 1929-06-29 | 1931-12-01 | Gen Aniline Works Inc | Manufacture of hydroxy carbazoles |
| DE1152107B (de) * | 1956-06-27 | 1963-08-01 | Chem Fab Promonta G M B H | Verfahren zur Herstellung von basisch substituierten Carbazolderivaten und deren Salzen |
| US3932424A (en) * | 1970-06-15 | 1976-01-13 | Richardson-Merrell Inc. | Bis-basic ethers of carbazole |
| BE789072A (fr) * | 1971-09-23 | 1973-03-21 | Astra Laekemedel Ab | Composes abaissant le taux de lipides du serum et leur obtention |
| AT336176B (de) * | 1971-12-10 | 1977-04-25 | Sandoz Ag | Verfahren zur herstellung eines pharmazeutischen praparates |
| US3975398A (en) * | 1973-08-01 | 1976-08-17 | Boehringer Mannheim G.M.B.H. | 9-Substituted 3-aminocarbazole compounds |
| DE2339396C2 (de) * | 1973-08-03 | 1984-06-28 | Boehringer Mannheim Gmbh, 6800 Mannheim | N-substituierte 1-Amino-3-phenoxypropan-2-ole, deren Salze, Verfahren zu deren Herstellung sowie Arzneimittel, die diese Verbindungen enthalten |
| DE2424523A1 (de) * | 1974-05-21 | 1975-12-11 | Boehringer Mannheim Gmbh | Neue 1,2,3,4-tetrahydrocarbazol-derivate und verfahren zu deren herstellung |
| US4152446A (en) * | 1974-11-16 | 1979-05-01 | Boehringer Mannheim Gmbh | Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases |
| US4076829A (en) * | 1974-11-16 | 1978-02-28 | Boehringer Mannheim Gmbh | Aminopropanol compounds and compositions for the treatment of cardiac and circulatory diseases |
| DE2454406A1 (de) * | 1974-11-16 | 1976-05-20 | Boehringer Mannheim Gmbh | Neue aminopropanol-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| GB1508208A (en) * | 1975-12-05 | 1978-04-19 | Ici Ltd | Amide derivatives |
| US4115409A (en) * | 1975-12-05 | 1978-09-19 | Imperial Chemical Industries Limited | Alkanolamine derivatives |
-
1978
- 1978-04-13 DE DE19782815926 patent/DE2815926A1/de not_active Withdrawn
-
1979
- 1979-04-02 CA CA324,667A patent/CA1129416A/en not_active Expired
- 1979-04-06 FI FI791142A patent/FI70406C/fi not_active IP Right Cessation
- 1979-04-06 SU SU792745301A patent/SU810079A3/ru active
- 1979-04-06 DK DK141979A patent/DK154555C/da not_active IP Right Cessation
- 1979-04-06 ES ES479396A patent/ES479396A1/es not_active Expired
- 1979-04-06 AU AU45820/79A patent/AU522975B2/en not_active Expired
- 1979-04-07 EP EP79101063A patent/EP0004920B1/de not_active Expired
- 1979-04-07 DE DE7979101063T patent/DE2960553D1/de not_active Expired
- 1979-04-08 IL IL57020A patent/IL57020A/xx unknown
- 1979-04-09 DD DD79212096A patent/DD143607A5/de not_active IP Right Cessation
- 1979-04-10 CS CS792434A patent/CS227007B2/cs unknown
- 1979-04-11 JP JP4311979A patent/JPS54157558A/ja active Granted
- 1979-04-11 ZA ZA791732A patent/ZA791732B/xx unknown
- 1979-04-12 AT AT0276279A patent/AT375639B/de not_active IP Right Cessation
- 1979-04-12 HU HU79BO1774A patent/HU179433B/hu unknown
-
1983
- 1983-04-04 US US06/479,921 patent/US4503067A/en not_active Expired - Lifetime
-
1984
- 1984-07-20 SG SG52284A patent/SG52284G/en unknown
-
1985
- 1985-01-10 HK HK23/85A patent/HK2385A/xx not_active IP Right Cessation
-
1987
- 1987-03-31 JP JP62076548A patent/JPS63258416A/ja active Pending
-
1991
- 1991-12-31 CS CS914200A patent/CS420091A3/cs unknown
-
1992
- 1992-06-25 MX MX9203380A patent/MX9203380A/es unknown
-
1993
- 1993-06-22 LU LU88320C patent/LU88320I2/de unknown
- 1993-06-29 NL NL930110C patent/NL930110I2/nl unknown
- 1993-09-27 LT LTRP1124A patent/LT2628B/xx unknown
-
1994
- 1994-02-28 BG BG098612A patent/BG61419B2/bg unknown
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4985454A (en) * | 1983-05-26 | 1991-01-15 | Boehringer Mannheim Gmbh | Process for the preparation of optically-active carbazole derivatives, new R- and S-carbazole derivatives and pharmaceutical compositions containing these compounds |
| US5071868A (en) * | 1983-05-26 | 1991-12-10 | Boehringer Mannheim Gmbh | Process for the preparation of optically-active carbazole derivatives, new r- and s-carbazole derivatives and pharmaceutical compositions containing these compounds |
| EP0893440A1 (en) * | 1997-07-22 | 1999-01-27 | Roche Diagnostics GmbH | Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it |
| WO1999005105A1 (en) * | 1997-07-22 | 1999-02-04 | Roche Diagnostics Gmbh | Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it |
| RU2202542C2 (ru) * | 1997-07-22 | 2003-04-20 | Рош Диагностикс Гмбх | Термодинамически стабильная модификация (±)1-(4-карбазолилокси)-3-[2-(2-метоксифенокси)этиламино]-2-пропанола , способ ее получения и содержащая ее фармацевтическая композиция |
| US6730326B2 (en) | 1997-07-22 | 2004-05-04 | Roche Diagnostics Gmbh | Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it |
| CZ296947B6 (cs) * | 1997-07-22 | 2006-08-16 | Roche Diagnostics Gmbh | Modifikace (+-)1-(4-karbazolyloxy)-3-[2-(2-methoxyfenoxy)ethylamino]-2-propanolu, zpusob její prípravy a izolace, farmaceutický prostredek s jejím obsahem a jeho pouzití |
| EP0918055A1 (en) * | 1997-11-24 | 1999-05-26 | Egis Gyogyszergyar Rt. | Process and intermediates for preparing 1-[9'H-carbazol-4'-yloxy]-3-[ 2''-(2'''- methoxy -phenoxy)-ethyl)-amino]-propan-2-ol[carvedilol] |
| EP1142873A3 (en) * | 1997-11-24 | 2003-09-10 | Egis Gyogyszergyar Rt. | Process for preparing 1-[9'H-carbazol-4'-yloxy]-3-[ 2''-(2'''- methoxy -phenoxy)-ethyl -amino]-propan-2-ol[carvedilol] |
| EP1142874A3 (en) * | 1997-11-24 | 2003-10-22 | Egis Gyogyszergyar Rt. | Intermediates for preparing the R or S enantiomer of 1-[9'H-carbazol-4'-yloxy]-3-[ 2''-(2'''- methoxy -phenoxy)-ethyl -amino]-propan-2-ol[carvedilol] |
| RU2245875C2 (ru) * | 1997-11-24 | 2005-02-10 | Эгиш Дьёдьсердьяр Рт. | Способ получения фармацевтического продукта |
| WO2004041783A1 (en) * | 2002-11-08 | 2004-05-21 | Zentiva, A.S. | Process for preparation of carvedilol |
Also Published As
| Publication number | Publication date |
|---|---|
| ES479396A1 (es) | 1980-04-16 |
| MX9203380A (es) | 1992-09-01 |
| NL930110I1 (nl) | 1993-10-18 |
| JPH0123462B2 (en:Method) | 1989-05-02 |
| JPS63258416A (ja) | 1988-10-25 |
| AU522975B2 (en) | 1982-07-08 |
| CA1129416A (en) | 1982-08-10 |
| IL57020A (en) | 1982-07-30 |
| HU179433B (en) | 1982-10-28 |
| FI70406C (fi) | 1986-09-19 |
| CS420091A3 (en) | 1992-04-15 |
| FI70406B (fi) | 1986-03-27 |
| DD143607A5 (de) | 1980-09-03 |
| DK141979A (da) | 1979-10-14 |
| AU4582079A (en) | 1979-10-18 |
| CS227007B2 (en) | 1984-04-16 |
| LT2628B (lt) | 1994-04-25 |
| DK154555B (da) | 1988-11-28 |
| SU810079A3 (ru) | 1981-02-28 |
| FI791142A7 (fi) | 1979-10-14 |
| DK154555C (da) | 1989-06-19 |
| ZA791732B (en) | 1980-05-28 |
| JPS54157558A (en) | 1979-12-12 |
| SG52284G (en) | 1985-03-29 |
| NL930110I2 (nl) | 1994-12-01 |
| AT375639B (de) | 1984-08-27 |
| DE2960553D1 (en) | 1981-11-05 |
| BG61419B2 (bg) | 1997-07-31 |
| ATA276279A (de) | 1984-01-15 |
| US4503067A (en) | 1985-03-05 |
| EP0004920B1 (de) | 1981-08-05 |
| EP0004920A1 (de) | 1979-10-31 |
| LU88320I2 (de) | 1994-05-04 |
| HK2385A (en) | 1985-01-18 |
| IL57020A0 (en) | 1979-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2815926A1 (de) | Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
| EP0014951B1 (de) | Heterocyclische Oxypropanolamin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| JP2637737B2 (ja) | 新規な薬剤 | |
| CH624102A5 (en:Method) | ||
| DE3631824A1 (de) | Cycloalkano(1.2-b)indol-sulfonamide | |
| DE3114239C2 (de) | N↑4↑-Carbamoylpiperazinpropanolderivate, Verfahren zu ihrer Herstellung und pharmazeutisches Mittel | |
| JPS6215062B2 (en:Method) | ||
| DE3411993A1 (de) | Substituierte benzopyrane, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimittel | |
| EP0199262A2 (de) | Fluorierte Benzyltriazolverbindungen | |
| EP0008645B1 (de) | Alkoxyphenylpyrrolidone, Verfahren zu ihrer Herstellung und Arzneimittel auf Basis dieser Verbindungen | |
| DE69719511T2 (de) | Antivirale 2,4-pyrimidindion-derivate und verfahren zu ihrer herstellung | |
| EP0014928A1 (de) | Neue Piperidinopropylderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| EP0041233B1 (de) | Substituierte Phenoxy-aminopropanol-Derivate, Zwischenprodukte und Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel | |
| EP0303920B1 (de) | Neue Benzofuranderivate und diese enthaltende therapeutische Mittel | |
| JPS648621B2 (en:Method) | ||
| EP0071950B1 (de) | Neue Heteroaryloxypropanolamine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| EP0586405B1 (de) | NEUE IN 4-STELLUNG DURCH ARYL ODER N-HETEROARYL SUBSTITUIERTE 2H-BENZO[b]PYRAN-DERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG SOWIE DIE VERBINDUNGEN ENTHALTENDE ZUBEREITUNGEN | |
| DE2740678A1 (de) | 1-amino-2-hydroxy-3-heterocycloxypropane | |
| CN113501795A (zh) | 一种新型重度抑郁症治疗药物伏硫西汀的制备方法 | |
| DE2217329A1 (de) | Benzofuranderivate | |
| EP0029992B1 (de) | Neue Aminopropanolderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2914166A1 (de) | Arylsubstituierte furane und verfahren zu ihrer herstellung | |
| EP0030030A1 (de) | Derivate des 2-Amino-äthanols, Verfahren zu ihrer Herstellung, pharmazeutische Präparate enthaltend solche Verbindungen und Verwendung von letzteren | |
| WO1994020466A1 (fr) | Nouveaux derives de la phenoxy-2 ethylamine, leur preparation et leur application en therapeutique | |
| US5391570A (en) | Aminomethyl-benzodioxane and benzopyran serotonergic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |